ReoPro Articles
Affimed's antithrombotic Ab completes proof-of-concept trial
11 December 2006
Guilford's Aggrastat sees strong results
23 May 2005
Guilford plans two new trials for Aggrastat
30 August 2004
Tokyo pharma stocks - week to July 5
12 July 2004
Japan's Fujisawa sets out plans for continuous growth
8 December 2003
Positive Phase IIb findings for ReoPro
2 June 2003
Fujisawa's tacrolimus in Phase III for IBD
11 March 2002
NICE "should appraise innovative new drugs a year before launch"
4 February 2002
ReoPro boosts survival in diabetics needing PCI
13 November 2001
ASSENT 3 trial shows new regimen benefit
24 August 2001
Texas gets approvable letter for Argatroban sNDA
23 July 2001
Retavase plus ReoPro improves AMI therapy
21 June 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
Disappointing sales for Integrilin; analyst
10 January 2001
New study shows no benefit for ReoPro
20 October 2000
New products boost growth at Eli Lilly
20 October 2000
Fujisawa drops migraine compound
5 October 2000
NICE-3 shows combination role for LMWH and antiplatelet agents
6 September 2000
Stock Commentary New York
31 August 2000
Lilly's ReoPro/stent better than Activase
11 August 2000
Eli Lilly's 2nd-qtr EPS increases 17%
25 July 2000
ReoPro plus Retavase in MI
21 June 2000
World thrombotics market forecasts
3 May 2000
Earnings rise 18% at Eli Lilly
17 April 2000
Genentech unveils new trials for tenecteplase
15 March 2000
COR's Integrilin sales could double to $127M
7 March 2000
COR boosted on early halt of Integrilin plus stenting study
7 February 2000
Eli Lilly suffers from poor Prozac sales
22 October 1999
Routine ReoPro use "cannot be justified"
7 September 1999
Roche's SYMPHONY study shows sibrafiban equivalence to aspirin
2 September 1999
Antiplatelet/thrombolytic combination: way forward for MI therapy?
1 September 1999
Fujisawa expanding tacrolimus indications
10 August 1999
EPISTENT results published
4 August 1999
Integrilin launched in first Euro markets
8 July 1999
Beyond Prozac : Lilly outlines future
14 June 1999
Stock Commentary New York
10 June 1999
First approval in EU for ReoPro plus stents
9 June 1999
P&U pursues novel antibiotics in $30m deal
7 April 1999
Celltech Makes Solid Six-Month Progress
16 December 1998
Centocor Sells Oncology Diagnostics
4 November 1998
FDA Rejects The Medicine Company's Hirulog
29 October 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Fujisawa Fights Back In Shrinking Domestic Market
15 September 1998
EPISTENT Update Confirms ReoPro Role In Stenting
1 September 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Integrilin Launched In First Market, The USA
4 June 1998
Aggrastat, Integrilin First ReoPro Competitors
21 May 1998
CellTech Makes Solid Six-Month Progress
19 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
Aggrastat Backed For Unstable Angina
14 April 1998
Integrilin "Approvable" In USA For Unstable Angina
8 April 1998
Combining Drugs With Interventional Cardiology
8 April 1998
Centocor Buys Retavase Rights For $335 Million
17 February 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
COR Gets Partial OK For Integrilin
4 February 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
PDL gpIIb/IIIa Antibody In Trials In Japan
27 January 1998
Israel OKs Extra Funding For New Drug Therapies
12 January 1998
Celltech Reflects On Pipeline After Mixed Fortunes In '97
16 December 1997
1997, An "Annus Horribilis" for Celltech
11 December 1997
ReoPro Sales To Reach $240 Million In 1997
11 December 1997
ReoPro Cleared For Expanded Use In UK
4 December 1997
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
Stock Commentary Europe
13 November 1997
ORBIT Data Support Phase III Studies Of Xemilofiban
13 November 1997
Stock Commentary New York
13 November 1997
ReoPro Approved For Expanded Usage
7 November 1997
Centocor To Report ReoPro Data In MI
6 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
